

# Akshara Singareeka Raghavendra

## List of Publications by Citations

**Source:**

<https://exaly.com/author-pdf/5470769/akshara-singareeka-raghavendra-publications-by-citations.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35 papers	437 citations	11 h-index	20 g-index
54 ext. papers	577 ext. citations	4.7 avg, IF	3.1 L-index

#	Paper	IF	Citations
35	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. <i>Nature Communications</i> , <b>2017</b> , 8, 15916	17.4	144
34	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3511-3517	2.2	55
33	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3996-4013	12.9	41
32	Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. <i>Nature Communications</i> , <b>2019</b> , 10, 657	17.4	30
31	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 345-351	4.3	20
30	Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. <i>Oncologist</i> , <b>2019</b> , 24, 313-318	5.7	20
29	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , <b>2017</b> , 123, 2422-2431	6.4	18
28	Mammographic breast density is associated with the development of contralateral breast cancer. <i>Cancer</i> , <b>2017</b> , 123, 1935-1940	6.4	16
27	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 509-514	8.7	14
26	Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, e7-e13	3	13
25	Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 518-524	7.3	11
24	Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 176, 227-234	4.4	8
23	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, e1283-e1288	3	8
22	Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1280-1285	10.3	7
21	Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 961-970	7.5	5
20	Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 789-804	5.2	4
19	The impact of smoking cessation on breast cancer patients' survival.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1542-1542	2.2	3

18	Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers. <i>Journal of Surgical Oncology</i> , <b>2020</b> , 121, 589-598	2.8	2
17	Inflammatory Breast Cancer Outcomes in a Contemporary Series. <i>Anticancer Research</i> , <b>2017</b> , 37, 5057-5063	2.3	2
16	Clinical findings and outcomes of MRI staging of breast cancer in a diverse population. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 315-324	4.4	2
15	Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 11	7.8	1
14	How Does MR Imaging Help Care for the Breast Cancer Patient? Perspective of a Medical Oncologist. <i>Magnetic Resonance Imaging Clinics of North America</i> , <b>2018</b> , 26, 289-293	1.6	1
13	Clinical findings and outcomes from MRI staging of breast cancers in women.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1124-1124	2.2	1
12	Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 559-559	2.2	1
11	Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1021-1021	2.2	1
10	A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 542-542	2.2	1
9	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 455-461	4.4	1
8	Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 46	7.8	1
7	Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1074-1074	2.2	
6	Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 260-260	2.2	
5	T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 585-585	2.2	
4	Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 580-580	2.2	
3	RADI-18. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, iii21-iii22	0.9	
2	RADI-17. Outcomes for patients with triple negative breast cancer treated with upfront stereotactic radiosurgery for brain metastases. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, iii21-iii21	0.9	
1	Reply to A. Pfof and C. Sidey-Gibbons.. <i>JCO Clinical Cancer Informatics</i> , <b>2022</b> , 6, e2100171	5.2	

